BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 27286458)

  • 1. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
    Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
    Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.
    Dai L; Li J; Ortega R; Qian W; Casiano CA; Zhang JY
    J Immunol Res; 2014; 2014():827827. PubMed ID: 24860838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer.
    Dai L; Li J; Xing M; Sanchez TW; Casiano CA; Zhang JY
    Prostate; 2016 Nov; 76(15):1375-86. PubMed ID: 27418398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
    Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
    J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort.
    Adeola HA; Smith M; Kaestner L; Blackburn JM; Zerbini LF
    Oncotarget; 2016 Mar; 7(12):13945-64. PubMed ID: 26885621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
    Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
    [No Abstract]   [Full Text] [Related]  

  • 7. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibody against new gene expressed in prostate protein is traceable in prostate cancer patients.
    Mohsenzadegan M; Saebi F; Yazdani M; Abolhasani M; Saemi N; Jahanbani F; Farajollahi MM
    Biomark Med; 2018 Oct; 12(10):1125-1138. PubMed ID: 30191737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
    O'Rourke DJ; DiJohnson DA; Caiazzo RJ; Nelson JC; Ure D; O'Leary MP; Richie JP; Liu BC
    Clin Chim Acta; 2012 Mar; 413(5-6):561-7. PubMed ID: 22146597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
    Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
    Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of Ra1A and its tissue-specific expression in hepatocellular carcinoma.
    Wang K; Chen Y; Liu S; Qiu S; Gao S; Huang X; Zhang J; Peng X; Qiani W; Zhang JY
    Int J Immunopathol Pharmacol; 2009; 22(3):735-43. PubMed ID: 19822090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens.
    Shi FD; Zhang JY; Liu D; Rearden A; Elliot M; Nachtsheim D; Daniels T; Casiano CA; Heeb MJ; Chan EK; Tan EM
    Prostate; 2005 May; 63(3):252-8. PubMed ID: 15538718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of esophageal cancer.
    Qin JJ; Wang XR; Wang P; Ren PF; Shi JX; Zhang HF; Xia JF; Wang KJ; Song CH; Dai LP; Zhang JY
    Asian Pac J Cancer Prev; 2014; 15(6):2635-40. PubMed ID: 24761876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
    Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
    Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
    Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
    Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer.
    Sun H; Shi JX; Zhang HF; Xing MT; Li P; Dai LP; Luo CL; Wang X; Wang P; Ye H; Li LX; Zhang JY
    Tumour Biol; 2017 Jun; 39(6):1010428317699132. PubMed ID: 28618923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis.
    Liu X; Chai Y; Li J; Ren P; Liu M; Dai L; Qian W; Li W; Zhang JY
    Tumour Biol; 2014 Mar; 35(3):2661-7. PubMed ID: 24399648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined serum and EPS-urine proteomic analysis using iTRAQ technology for discovery of potential prostate cancer biomarkers.
    Zhang M; Chen L; Yuan Z; Yang Z; Li Y; Shan L; Yin B; Fei X; Miao J; Song Y
    Discov Med; 2016 Nov; 22(122):281-295. PubMed ID: 28009970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.